tbuckley/cabot-search huggingface dataset:
Oedema over an inoculation site
Authors: Nicholas Beng Hui Ng, Rajeev Ramachandran
Journal: BMJ (2020)

An 18 month old girl presented to the children’s emergency department with five days of fever (up to 40°C) associated with painful swelling in the left side of her neck. She had no accompanying respiratory symptoms. On examination, she had tender cervical lymph node enlargement with the largest node measuring 3×3 cm at the left anterior cervical chain. In addition, there was redness and oedema over the previously healed site of her BCG vaccine inoculation on the left upper arm (fig 1) (she had received this vaccine at birth, as per the local vaccination schedule). She had no conjunctival injection, mucosal erythema, oedema over the …
Impacts of Coal Use on Health
Authors: Michael Hendryx, Keith J. Zullig, Juhua Luo
Journal: Annual Review of Public Health (2020)

This article reviews evidence for the public health impacts of coal across the extraction, processing, use, and waste disposal continuum. Surface coal mining and processing impose public health risks on residential communities through air and water pollution. Burning coal in power plants emits more nitrogen oxides, sulfur dioxide, particulate matter, and heavy metals per unit of energy than any other fuel source and impairs global public health. Coal ash disposal exposes communities to heavy metals and particulate matter waste. Use of coal in domestic households causes public health harm concentrated in developing nations. Across the coal continuum, adverse impacts are disproportionately felt by persons of poor socioeconomic status, contributing to health inequities. Despite efforts to develop renewable energy sources, coal use has not declined on a global scale. Concentrated efforts to eliminate coal as an energy source are imperative to improve public health and avert serious climate change consequences.
Neoadjuvant Sipuleucel-T in Localized Prostate Cancer: Effects on Immune Cells within the Prostate Tumor Microenvironment
Authors: L. Fong, V. Weinberg, S. Chan, J. Corman, C. Amling, R.A. Stephenson, J. Simko, R.B. Sims, P. Carroll, E.J. Small
Journal: Annals of Oncology (2012)
A new medical device for in vivo capturing of circulating tumor cells in breast cancer (BC) patients.
Authors: Dawid Murawa, Stefanie Herold, Phillip Sangwook Kim, Arndt Schmitz, Thomas Krahn, Pawel Murawa, Maciej Zabel, Nils G. Morgenthaler, Piotr Nowaczyk, Klaus Luecke
Journal: Journal of Clinical Oncology (2012)

10537 Background: In BC, the number of circulating tumor cells (CTCs) is discussed as a prognostic and stratification biomarker, and could also reflect treatment efficacy. Currently, CTCs are isolated ex vivo from a small volume of blood. Results from a larger volume of blood are scarce. The aim of the study was to assess a functionalized and structured medical wire (FSMW) for in vivo capturing of CTCs directly from the blood stream of BC patients. Methods: The device was inserted in a cubital vein through a standard cannula for thirty minutes. The interaction of target CTCs with the FSMW was mediated by antibodies directed against the epithelial cell adhesion molecule (EpCAM). To confirm binding of CTCs to the wire, the immunohistochemical positive staining against EpCAM as well as negative staining for CD45 was performed. There were 54 applications of the wire in 42 stage I-IV BC patients (12 double applications). Enumeration data from 37 BC patients with 49 applications (5 failed subsequent analyses) were assessed. CTC counts on 23 devices were directly compared to counts by CellSearch. Results: The device was well tolerated in all 54 applications without side effects. We obtained in vivo isolation of CTCs in 44 of 49 applications to BC patients (89.7 %). The sensitivity was similar for early and late stage BC patients. The median (range) of isolated EpCAM-positive CTCs was 5 (0-515). The CellSearch method reached a sensitivity of 18.5%. In all paired samples the number of CTCs detected with the FSMW was higher or equal to CellSearch, regardless of the disease stage. Linear regression of the data of the double application of the FSMW showed a very good concordance (r 2 = 0.97, p&lt;0.0001). Conclusions: Whilst well tolerated without side effects, the CTC detection rate of the FSMW in BC patients was nearly 90 %. CTC detection was obtained in 18.5% by the CellSearch. Double application of FSMWs in the same patient indicates ample precision. This proof of concept study may have important clinical implications, as the device may improve early detection, prognosis and therapy monitoring of BC patients. The molecular analysis of the captured CTCs could become a breakthrough in personalized medicine.
Abstract 227: Sudden Cardiac Arrest During Exercise Occurs Infrequently and With Few Warning Symptoms
Authors: Katherine S Allan, Brian E Grunau, Morgan Haines, Armin Nowroozpoor, James Christenson, Floyd Besserer, Christopher Fordyce, Paul Dorian, Steve Lin
Journal: Circulation (2019)

Introduction: The incidence and details of sudden cardiac arrest (SCA) during exercise in the general population are not well described. We describe a cohort ages 2-85 who experienced an SCA within ≤ 1 hour of moderate to vigorous activity in 4 metropolitan areas of British Columbia, Canada. Methods: We reviewed prehospital records of consecutive out-of-hospital cardiac arrests (OHCAs) in the provincial BC OHCA Registry from June 17 2017 to August 16 2018. We included non-traumatic OHCAs treated by EMS occurring within ≤ 1 hour of exercise. We defined SCA as an OHCA of no obvious cause, witnessed/unwitnessed, survived/died. We assigned an estimated metabolic equivalent (MET) score to each type of physical activity. We defined moderate exercise as a MET score of 3-5.9 and vigorous as ≥6. Results: A total of 2674 OHCAs occurred during the study period of which 56 SCAs (2.1%) occurred within ≤1 hour of participation in 23 types of exercise (Figure 1). The incidence of SCA during exercise was 1.45 (95% CI 1.10-1.88) per 100,000 population. The median age was 56.5 [IQR 45-69] and 87.5% (49/56) were male. Most exercise related SCAs occurred in public (49/56 87.5%), 83.3% (45/54) were bystander witnessed and 85% (46/54) received bystander CPR. Over 70% (40/56) had a shockable rhythm. The survival rate was 55.4% (31/56). Half of the SCAs collapsed during exercise (49.1%; 26/53) while the other half collapsed within ≤1 hour after exercising (51%; 27/53). Symptom data were available in 46% of patients (23/50) with most experiencing chest pain, dizziness, feeling unwell or seizure just prior to collapse. Conclusions: SCAs during exercise are rare and frequently occur in a public location. Survival is high and may be related to witnessed and public location status. Equal numbers of SCAs collapsed during or ≤ 1 hour of exercising and symptoms were present in almost half. Future research is needed to determine what factors could predict those at highest risk for SCA in order to prevent future events.
Prostate Cancer Stem Cells Display Lowered Activity of the mTOR Pathway and Resistance against mTOR Inhibition Caused by Elevated Hypoxic Signaling
Authors: M. Marhold, E. Tomasich, A. Haschemi, G. Hofbauer, A. Spittler, M. Krainer, P. Horak
Journal: Annals of Oncology (2012)
Lung Malignancies and Second Neoplasias in Patients with Hodgkińs Lymphoma
Authors: E. Almagro-Casado, D. Pérez-Callejo, A. López-González, P. Ibeas, A. Ruiz-Valdepeñas, M. Palka, C. Maximiano, M. Méndez García, S. Mellor, M. Provencio Pulla
Journal: Annals of Oncology (2012)
Effect of Germline Polymorphisms of DNA Repair Genes on Chemotherapy Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
Authors: I.G. Sullivan, M. Majem Tarruella, D. Páez, C. Pallarés, L. Paré, E. Del Rio, A. Lopez Pousa, A. Barnadas, T. Ramón Y Cajal, M. Baiget
Journal: Annals of Oncology (2012)
Phase I Trial of Irreversible Pan-Erbb Inhibitor Dacomitinib (DAC) in Combination with ALK/MET Inhibitor Crizotinib (CRIZ) in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)
Authors: P.A. Janne, A.T. Shaw, G. Giaccone, D.R. Camidge, S.M. Shreeve, Z. Goldberg, Y. Tang, B. Solomon
Journal: Annals of Oncology (2012)
Immunoglobulin Prophylaxis against Cytomegalovirus Infection in Patients at High Risk Ofinfection Following Allogeneic Hematopoietic Cell Transplantation
Authors: H. Ichihara, H. Nakamae, A. Hirose, T. Nakane, H. Koh, Y. Hayashi, M. Nisimoto, M. Nakamae, Y. Terada, S. Koh, T. Yoshimura, M. Aimoto, M. Manabe, K. Hagiwara, M. Hino
Journal: Annals of Oncology (2012)
P-0064 ERCC1 Overexpression Predicts Poor Prognosis in Patients with Gastric/GE Junction Adenocarcinoma Treated with Adjuvant Cisplatin-Based Chemotherapy
Authors: Sara De Dosso, Martina Nucifora, Elena Zanellato, Renzo Boldorini, Sonzogni Angelica, Nicola Fazio, Roberto Biffi, Eraldo Bucci, Mazzucchelli Luca, Milo Frattini, Piercarlo Saletti
Journal: Annals of Oncology (2012)
Interleukin-8 (IL8) as a Biomarker of Response and Survival With Anti-Angiogenic Agents: A Proof-of-Concept from the Pazopanib (PZP) Series in Urothelial Cancer (UC)
Authors: A. Necchi, L. Mariani, N. Zaffaroni, N. Nicolai, P. Giannatempo, C. Morosi, M.G. Daidone, A.M. Gianni, F.G.M. De Braud, R. Salvioni
Journal: Annals of Oncology (2012)
凝集誘発発光色素と金ナノ粒子を共に搭載したナノプローブを用いたin vivo腫瘍標的化デュアルモーダル蛍光/CTイメージング | 文献情報 | J-GLOBAL 科学技術総合リンクセンター
Authors: Zhang Jimei, Li Chan, Zhang Xu, Huo Shuaidong, Jin Shubin, AN Fei-fei, Wang Xiaodan, Xue Xiangdong, Okeke C.i., Duan Guiyun, Guo Fengguang, Zhang Xiaohong, Hao Jifu, C Wang Paul, Zhang Jinchao, Liang Xing-jie
Journal: Biomaterials (2015)
External Validation of the Association of Progression-Free Survival at 6 Months (PFS6) with Overall Survival at 12 Months (OS12) in Second-Line Therapy for Advanced Urothelial Carcinoma (UC)
Authors: G. Sonpavde, B. Maughan, K.M. Boucher, R. Fougeray, T.K. Choueiri, G. Niegisch, Y. Wong, S.S. Sridhar, C.N. Sternberg, J. Bellmunt
Journal: Annals of Oncology (2012)
Whole-Genome Sequencing of Finnish Type 1 Diabetic Siblings Discordant for Kidney Disease Reveals DNA Variants associated with Diabetic Nephropathy
Authors: Jing Guo, Owen J. L. Rackham, Niina Sandholm, Bing He, Anne-May Österholm, Erkka Valo, Valma Harjutsalo, Carol Forsblom, Iiro Toppila, Maija Parkkonen, Qibin Li, Wenjuan Zhu, Nathan Harmston, Sonia Chothani, Miina K. Öhman, Eudora Eng, Yang Sun, Enrico Petretto, Per-Henrik Groop, Karl Tryggvason
Journal: Journal of the American Society of Nephrology (2020)

Several genetic susceptibility loci associated with diabetic nephropathy have been documented, but no causative variants implying novel pathogenetic mechanisms have been elucidated.We carried out whole-genome sequencing of a discovery cohort of Finnish siblings with type 1 diabetes who were discordant for the presence (case) or absence (control) of diabetic nephropathy. Controls had diabetes without complications for 15-37 years. We analyzed and annotated variants at genome, gene, and single-nucleotide variant levels. We then replicated the associated variants, genes, and regions in a replication cohort from the Finnish Diabetic Nephropathy study that included 3531 unrelated Finns with type 1 diabetes.We observed protein-altering variants and an enrichment of variants in regions associated with the presence or absence of diabetic nephropathy. The replication cohort confirmed variants in both regulatory and protein-coding regions. We also observed that diabetic nephropathy-associated variants, when clustered at the gene level, are enriched in a core protein-interaction network representing proteins essential for podocyte function. These genes include protein kinases (protein kinase C isoforms ε and ι) and protein tyrosine kinase 2.Our comprehensive analysis of a diabetic nephropathy cohort of siblings with type 1 diabetes who were discordant for kidney disease points to variants and genes that are potentially causative or protective for diabetic nephropathy. This includes variants in two isoforms of the protein kinase C family not previously linked to diabetic nephropathy, adding support to previous hypotheses that the protein kinase C family members play a role in diabetic nephropathy and might be attractive therapeutic targets.
Genetic variants in the folate metabolic pathway genes predict cutaneous melanoma‐specific survival
Authors: W. Dai, H. Liu, Y. Liu, X. Xu, D. Qian, S. Luo, E. Cho, D. Zhu, C.I. Amos, S. Fang, J.E. Lee, X. Li, H. Nan, C. Li, Q. Wei
Journal: British Journal of Dermatology (2020)

Folate metabolism plays an important role in DNA methylation and nucleic acid synthesis and thus may function as a regulatory factor in cancer development. Genome-wide association studies (GWASs) have identified some single-nucleotide polymorphisms (SNPs) associated with cutaneous melanoma-specific survival (CMSS), but no SNPs were found in genes involved in the folate metabolic pathway. To examine associations between SNPs in folate metabolic pathway genes and CMSS. We comprehensively evaluated 2645 (422 genotyped and 2223 imputed) common SNPs in folate metabolic pathway genes from a published GWAS of 858 patients from The University of Texas MD Anderson Cancer Center and performed the validation in another GWAS of 409 patients from the Nurses' Health Study and Health Professionals Follow-up Study, in which 95/858 (11·1%) and 48/409 (11·7%) patients died of cutaneous melanoma, respectively. We identified two independent SNPs (MTHFD1 rs1950902 G>A and ALPL rs10917006 C>T) to be associated with CMSS in both datasets, and their meta-analysis yielded an allelic hazards ratio of 1·75 (95% confidence interval 1·32-2·32, P = 9·96 × 10-5 ) and 2·05 (1·39-3·01, P = 2·84 × 10-4 ), respectively. The genotype-phenotype correlation analyses provided additional support for the biological plausibility of these two variants' roles in tumour progression, suggesting that variation in SNP-related mRNA expression levels is likely to be the mechanism underlying the observed associations with CMSS. Two possibly functional genetic variants, MTHFD1 rs1950902 and ALPL rs10917006, were likely to be independently or jointly associated with CMSS, which may add to personalized treatment in the future, once further validated. What is already known about this topic? Existing data show that survival rates vary among patients with melanoma with similar clinical characteristics; therefore, it is necessary to identify additional complementary biomarkers for melanoma-specific prognosis. A hypothesis-driven approach, by pooling the effects of single-nucleotide polymorphisms (SNPs) in a specific biological pathway as genetic risk scores, may provide a prognostic utility, and genetic variants of genes in folate metabolism have been reported to be associated with cancer risk. What does this study add? Two genetic variants in the folate metabolic pathway genes, MTHFD1 rs1950902 and ALPL rs10917006, are significantly associated with cutaneous melanoma-specific survival (CMSS). What is the translational message? The identification of genetic variants will make a risk-prediction model possible for CMSS. The SNPs in the folate metabolic pathway genes, once validated in larger studies, may be useful in the personalized management and treatment of patients with cutaneous melanoma.
Population Movement Patterns Among the Democratic Republic of the Congo, Rwanda, and Uganda During an Outbreak of Ebola Virus Disease: Results from Community Engagement in Two Districts — Uganda, March 2019
Authors: Lydia Nakiire, Herman Mwanja, Satish K. Pillai, Jonan Gasanani, Dickson Ntungire, Stephen Nsabiyumva, Richardson Mafigiri, Nick Muneza, Sarah E. Ward, Zeinabou Daffe, Peter Babigumira Ahabwe, Simon Kyazze, Joseph Ojwang, Jaco Homsy, Elvira Mclntyre, Mohammed Lamorde, Richard Walwema, Issa Makumbi, Allan Muruta, Rebecca D. Merrill
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

Trade and business, need for health care, visits to family, refugee support, and insecurity in the Democratic Republic of the Congo (DRC) drive population movement patterns among Rwanda, Uganda, and the provinces in eastern DRC that are experiencing an Ebola virus disease outbreak.
Elite Intratumoral T-cell Clonotypes (The 1%) Effect “Trickle-Down Cytotoxicity”
Authors: Brian S. Henick
Journal: Clinical Cancer Research (2020)

Abstract Careful study of T-cell clonal dynamics in patients with non–small cell lung cancer treated with neoadjuvant nivolumab suggests that successful trafficking of clones from a proliferative burst in the periphery to the tumor associates with major pathologic response. Integration of these findings with functional analysis may augment current therapeutic strategies. See related article by Zhang et al., p. 1327
P-0068 The 7th Edition of the TNM Classification for Gastric Cancer and a Proposal of a New Classification for D2 Gastrectomy
Authors: Vincenzo Catalano, Valerio Sisti, Daniele Spada, Francesco Graziano, Paolo Giordani, Paolo Alessandroni, Anna Baldelli, Virginia Casadei, David Rossi, Silvia D'Emidio, Stefano Luzi Fedeli, Michele De Nictolis, Enrica Testa, Giammaria Fiorentini, Costantino Zingaretti
Journal: Annals of Oncology (2012)
Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution
Authors: Michelle Chan-Seng-Yue, Jaeseung C. Kim, Gavin W. Wilson, Karen Ng, Eugenia Flores Figueroa, Grainne M. O’Kane, Ashton A. Connor, Robert E. Denroche, Robert C. Grant, Jessica McLeod, Julie M. Wilson, Gun Ho Jang, Amy Zhang, Anna Dodd, Sheng-Ben Liang, Ayelet Borgida, Dianne Chadwick, Sangeetha Kalimuthu, Ilinca Lungu, John M. S. Bartlett, Paul M. Krzyzanowski, Vandana Sandhu, Hervé Tiriac, Fieke E. M. Froeling, Joanna M. Karasinska, James T. Topham, Daniel J. Renouf, David F. Schaeffer, Steven J. M. Jones, Marco A. Marra, Janessa Laskin, Runjan Chetty, Lincoln D. Stein, George Zogopoulos, Benjamin Haibe-Kains, Peter J. Campbell, David A. Tuveson, Jennifer J. Knox, Sandra E. Fischer, Steven Gallinger, Faiyaz Notta
Journal: Nature Genetics (2020)
Prognostic Value of Vasodilator Stress Perfusion CMR in Morbidly Obese Patients (BMI ≥40 kg/m2) Without Known CAD
Authors: Marine Kinnel, Jérôme Garot, Théo Pezel, Thomas Hovasse, Thierry Unterseeh, Stéphane Champagne, Yves Louvard, Marie Claude Morice, Philippe Garot, Francesca Sanguineti
Journal: JACC. Cardiovascular imaging (2020)
Dead/H (ASP-GLU-ALA-ASP/HIS) Box Polypeptide 3, X-Linked Plays an Oncogenic Roles to Induce Cancer Stem Cell-Like Properties
Authors: K. Nozaki, H. Kagamu, K. Ichikawa, J. Koshio, Y. Saida, T. Tanaka, S. Miura, S. Watanabe, H. Yoshizawa, I. Narita
Journal: Annals of Oncology (2012)
Older Patients with Biliary Tract Cancer: Treatment and Prognosis
Authors: S.H. Lee, B.S. Lee, S.E. Jang, D.-W. Ahn, J.-H. Hwang, D.W. Hwang, J.Y. Cho, Y.-S. Yoon, H.-S. Han, S. Ahn
Journal: Annals of Oncology (2012)
In search of an anti-inflammatory drug for Alzheimer disease
Authors: Erika Gyengesi, Gerald Münch
Journal: Nature Reviews Neurology (2020)

Evidence suggests that chronic neuroinflammation has an important role in the pathogenesis of Alzheimer disease. However, in a new clinical trial, the tetracycline antibiotic minocycline, which has anti-inflammatory properties, failed to delay disease progression in individuals with mild Alzheimer disease.
A Multi-Center, Middle East, Phase II Study of the Raf-Kinase Inhibitor Sorafenib in Patients with Advanced Renal Cell Carcinoma
Authors: H.M. Khaled, H. Abdel Azim, E. Barsoum, G. Chahine, A. Shamseddine, G. Abdel Metaal, A. Omar, A.R. Jazeih, A. Badran
Journal: Annals of Oncology (2012)
Feasibility of Personalized Therapy with Lenalidomide in Transplantation-Ineligible Myeloma Patients According to the European Myeloma Network Recommendation
Authors: S. Ito, T. Mine, T. Sugawara, Y. Fujishima, R. Sasaki, T. Oyake, K. Murai, Y. Ishida
Journal: Annals of Oncology (2012)
Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder
Authors: Andrea Necchi, Russell Madison, Daniele Raggi, Joseph M. Jacob, Gennady Bratslavsky, Oleg Shapiro, Julia A. Elvin, Jo-Anne Vergilio, Jonathan K. Killian, Nhu Ngo, Shakti Ramkissoon, Eric Severson, Amanda C. Hemmerich, Richard Huang, Siraj M. Ali, Jon H. Chung, Prasanth Reddy, Vincent A. Miller, Alexa B. Schrock, Laurie M. Gay, Brian M. Alexander, Petros Grivas, Jeffrey S. Ross
Journal: European Urology (2020)
Using cancer patient stories to “power” communication modules.
Authors: Forrest Lang, Joseph Sobol
Journal: Journal of Clinical Oncology (2012)

TPS9147 Background: Caring for patients with cancer poses great challenges to doctors’ communication skills. This project, funded by NIH-NCI, represents an innovative collaboration between ETSU faculty in medical oncology, family medicine, and storytelling. The team secures patients’ and caregivers’ cooperation in recording stories of their journeys with illness. These are the focus of a set of cancer communication modules, to be offered as educational experiences for medical students, residents, and oncology fellows. The modules in development address 1) breaking bad news, 2) living through treatment, 3) transitioning from curative to palliative care, 4) communicating with family, and 5) sensitivity to issues of religion and spirituality. Methods: A collaborative inter-professional team developed an interview protocol to facilitate sharing of cancer-themed narratives. Video records are transcribed and coded using N-Vivo 8. The rating team meets to identify video clips that speak powerfully to positive, negative, or ambivalent aspects of cancer communication. Selected patients are brought together into “story circles,” where additional narratives are gathered. The module development team uses these stories to create empathic involvement in viewers, and to sensitize them to effective and ineffective communication strategies and challenges surrounding critical moments in patients’ lived experience of cancer. Modules effectiveness is tested with 1) Family Medicine and Internal Medicine residents, 2) medical oncology fellows and 3) multi-professionals health students just completing a communication courses. Assessment includes a pre-test and post-test OSCE addressing a number of the challenging cancer communication moments. Eighty-four of a projected 100 patient interviews and twelve physician//faculty interviews have been recorded, and all have agreed to the use of their interview materials. Representative examples of recorded cancer stories will be presented to demonstrate their evocative and pedagogical value. Opportunities will be discussed for further uses of these and similar stories in collaborations between medicine and the arts and humanities.
Safety Report of a Phase II Trial of Irinotecan Plus S-1 (Iris) with Cetuximab in Pre-Treated Patients with KRAS Wild Type of Metastatic Colorectal Cancer: HGCSG0902
Authors: Y. Komatsu, S. Yuki, Y. Kawamoto, H. Hayashi, T. Kato, A. Hosokawa, I. Iwanaga, O. Muto, K. Hatanaka, M. Nakamura, Y. Tsuji, M. Tateyama, H. Fukushima, M. Kudo, Y. Sakata
Journal: Annals of Oncology (2012)
<i>SLC43A3</i> Is a Biomarker of Sensitivity to the Telomeric DNA Damage Mediator 6-Thio-2′-Deoxyguanosine
Authors: Ilgen Mender, Kimberly Batten, Michael Peyton, Aishwarya Vemula, Crystal Cornelius, Luc Girard, Boning Gao, John D. Minna, Jerry W. Shay
Journal: Cancer Research (2020)

Cell membrane transporters facilitate the passage of nucleobases and nucleosides for nucleotide synthesis and metabolism, and are important for the delivery of nucleoside analogues used in anticancer drug therapy. Here, we investigated if cell membrane transporters are involved in the cellular uptake of the nucleoside analogue DNA damage mediator 6-thio-2'-deoxyguanosine (6-thio-dG). A large panel of non-small cell lung cancer (NSCLC) cell lines (73 of 77) were sensitive to 6-thio-dG; only four NSCLC lines were resistant to 6-thio-dG. When analyzed by microarray and RNA sequencing, the resistant NSCLC cell lines clustered together, providing a molecular signature for patients that may not respond to 6-thio-dG. Significant downregulation of solute carrier family 43 A3 (